Administration of Fingolimod in Greek Patients With Multiple Sclerosis.
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorElpen Pharmaceutical Co. Inc.
About this trial
The goal of this observational study is to evaluate the efficacy of fingolimod through the estimation of the annualized relapse rate (ARR) over a period of 2 years.
Participants who are already taking fingolimod as part of their regular medical care for MS will answer questions about their medical history for the past 1 year and for their status for the next 2 years.
Eligibility criteria
Qualifiers
Patients over 18 years of age.
Consent and compliance of participants with the treatments and procedures of the study.
Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) according to the revised McDonald 2017 criteria.
Patients who are receiving fingolimod, according to the drug's Summary of product Characteristics (SmPC).
Disqualifiers
Patients under 18 years of age.
Patients with a contraindication to taking fingolimod according to the drug's Summary of product Characteristics (SmPC).
Patients with a history of mental illness, substance abuse, to a degree that may prevent their participation in the study.
Patients participating in another research protocol.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
140 Participants
are grouped into 1 trial groupLocations
Sponsors and collaborators
Elpen Pharmaceutical Co. Inc.
Lead sponsor
AHEPA University Hospital
Collaborator
Source ClinicalTrials.gov